Related Experiment Video
Updated: Apr 12, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
Published on: March 18, 2015
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway
Chung-Yu Ku1, Ying-Ren Wang1, Hsuan-Yuan Lin2
1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Abstract:
Inhibition of VEGFR2 activity has been proposed as an important strategy for the clinical treatment of hepatocellular carcinoma (HCC). In this study, we identified corosolic acid (CA), which exists in the root of Actinidia chinensis, as having a significant anti-cancer effect on HCC cells. We found that CA inhibits VEGFR2 kinase activity by directly interacting with the ATP binding pocket. CA down-regulates the VEGFR2/Src/FAK/cdc42 axis, subsequently decreasing F-actin formation and migratory activity in vitro. In an in vivo model, CA exhibited an effective dose (5 mg/kg/day) on tumor growth. We further demonstrate that CA has a synergistic effect with sorafenib within a wide range of concentrations. In conclusion, this research elucidates the effects and molecular mechanism for CA on HCC cells and suggests that CA could be a therapeutic or adjuvant strategy for patients with aggressive HCC.
Insights
Corosolic acid (CA) from Actinidia chinensis inhibits hepatocellular carcinoma (HCC) growth by targeting VEGFR2. CA shows synergistic effects with sorafenib, offering a potential therapeutic strategy for aggressive HCC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) treatment often involves targeting vascular endothelial growth factor receptor 2 (VEGFR2).
- Identifying novel therapeutic agents for HCC is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the anti-cancer effects and molecular mechanisms of corosolic acid (CA) on HCC cells.
- To evaluate CA's potential as a therapeutic or adjuvant strategy for HCC.
Main Methods:
- In vitro kinase assays to assess CA's interaction with VEGFR2 ATP binding pocket.
- Cellular assays to analyze the VEGFR2/Src/FAK/cdc42 signaling pathway and cell migration.
- In vivo studies using a mouse model to evaluate CA's efficacy on tumor growth.
- Combination studies with sorafenib to assess synergistic effects.
Main Results:
- Corosolic acid (CA) directly inhibits VEGFR2 kinase activity.
- CA down-regulates the VEGFR2/Src/FAK/cdc42 axis, reducing F-actin formation and cell migration in vitro.
- CA demonstrated effective dose-dependent inhibition of tumor growth in vivo (5 mg/kg/day).
- CA exhibited a synergistic effect with sorafenib across various concentrations.
Conclusions:
- Corosolic acid (CA) possesses significant anti-cancer properties against HCC by inhibiting VEGFR2 signaling.
- CA's ability to disrupt the VEGFR2/Src/FAK/cdc42 pathway and reduce tumor growth suggests its therapeutic potential.
- CA may serve as a valuable therapeutic or adjuvant agent for patients with aggressive HCC, potentially in combination with existing treatments like sorafenib.
More Related Videos
Related Concept Videos
Cancer Cell Migration through Invadopodia
Cell Migration
Cell Migration
Inhibition of Cdk Activity
Inhibition of CDK Activity
Intracellular Signaling Affects Focal Adhesions
Some...

